Determining the Mechanisms of Loss of CAR T Cell Persistence
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A prospective observational study of pediatric and young adult acute lymphoblastic leukaemia (ALL) patients treated with CD19 chimeric antigen receptor T-cells (CAR-T cells). The study will examine changes in CAR-T persistence over time and causal factors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dzieci i młodzi dorośli (do 25 lat) z białaczką limfoblastyczną, która powróciła lub nie poddaje się leczeniu
- •Pacjenci zaplanowani do leczenia zatwierdzonymi komórkami CAR-T skierowanymi na CD19
- •Pisemna zgoda rodzica lub opiekuna na uczestnictwo w badaniu
✗ Disqualifies
- •Pacjenci już uczestniczący w innym badaniu klinicznym z innymi komórkami CAR-T
- •Osoby, które mogą mieć trudności z realizacją wymogów badania
Simplified criteria — AI translation
Trial details
- Maximum age
- 25 Years
- Last updated (source)
- August 7, 2026
- Sex
- No restrictions
Locations (3)
Great Ormond Street Hospital
London, United Kingdom
University College London Hospital
London, United Kingdom
Royal Manchester Children's Hospital
Manchester, United Kingdom
Trial contact
CARPERS Trial Manager
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.